Most people meet C-reactive protein in a hospital, where a high reading signals an infection or a flare-up of something acute. But there is a second, quieter story in that same molecule. Measured with a sensitive assay and read at the low end of the range, hs-CRP — high-sensitivity C-reactive protein — becomes one of the most accessible windows we have onto the slow, smouldering inflammation that longevity scientists now think of as a core driver of ageing.
This article explains what hs-CRP is, why ageing research keeps coming back to it, what the cardiovascular evidence actually shows, how to read your own number sensibly, and what the research associates with a lower result. It is educational, not medical advice — every substantive claim is cited, and the limitations are spelled out as we go.
What hs-CRP actually measures
C-reactive protein is made by the liver in response to signalling molecules — chiefly interleukin-6 (IL-6) — released when the immune system is activated. It is one of the body's "acute-phase" proteins: in a serious infection, levels can climb a hundredfold within a day or two, which is why the standard CRP test has long been used to detect and monitor acute illness.
The high-sensitivity version of the test is the same molecule measured with a more precise assay that can resolve the small differences at the bottom of the range — the difference between, say, 0.5 and 2.5 mg/L. Those low-end values are too subtle to matter for diagnosing an infection, but they turn out to carry information about something else entirely: the persistent, low-grade inflammatory tone a person carries when they are not acutely ill. That background tone is what makes hs-CRP interesting for healthy-ageing, rather than just for emergency medicine.
It is worth being clear about what the marker is and is not. hs-CRP is a downstream read-out — a summary of how much inflammatory signalling is going on — not a cause in itself. It does not tell you where inflammation is coming from. A single high reading can mean a recent cold, a flare of arthritis, a hard workout the day before, or genuine chronic inflammation. That non-specificity is the marker's main limitation, and it shapes how the number should be interpreted, as we will see.
Inflammaging: why a little inflammation tracks ageing
In 2000, the immunologist Claudio Franceschi proposed that ageing is accompanied by a chronic, low-grade, systemic inflammatory state, and coined the term "inflamm-aging" to describe it (Franceschi et al., 2000, Annals of the New York Academy of Sciences). The idea was that decades of exposure to stressors — infections, damaged cells, misplaced molecules from our own tissues, an ageing immune system — leave the body in a state of mild, persistent inflammatory activation that quietly rises with the years.
Two decades of work turned that hypothesis into one of the organising ideas of modern geroscience. In an updated synthesis, Franceschi and colleagues described inflammaging as a "chronic, sterile, low-grade inflammation" that develops with age and "contributes to the pathogenesis of age-related diseases" (Franceschi et al., 2018, Nature Reviews Endocrinology). The same low-grade inflammation appears as a thread running through several of the conditions that dominate later life — cardiovascular disease, type 2 diabetes, neurodegeneration, frailty and some cancers — which is why researchers treat it as a shared mechanism of ageing rather than a feature of any single disease.
hs-CRP earns its place in this story because it is the most practical, widely available blood marker that moves with that background inflammatory tone. It is cheap, standardised and measurable from an ordinary blood draw — which makes it a usable proxy for a process that is otherwise hard to see.
What the cardiovascular evidence shows
The strongest body of evidence linking hs-CRP to a real ageing-related outcome is in cardiovascular disease, and it is worth walking through it carefully because it illustrates both the marker's value and its nuance.
First, the association. In a pooled analysis of individual data from 160,309 people without a history of vascular disease, the Emerging Risk Factors Collaboration found that higher CRP concentrations were associated with greater risk of coronary heart disease, ischaemic stroke and vascular death. After adjusting for conventional risk factors, each one-standard-deviation higher level of log-CRP carried roughly a 30–40% higher risk of coronary heart disease (Emerging Risk Factors Collaboration, 2010, The Lancet). That is a robust, dose-dependent relationship across a very large sample.
Second, prediction translating into action. The JUPITER trial randomised 17,802 apparently healthy people who had normal LDL cholesterol (below 130 mg/dL) but elevated hs-CRP (2.0 mg/L or higher) to a statin or placebo. The statin group had about a 44% lower rate of major cardiovascular events (Ridker et al., 2008, New England Journal of Medicine). In other words, an elevated hs-CRP identified people who looked low-risk on cholesterol alone but who measurably benefited from treatment — evidence that the marker adds information beyond the standard lipid panel.
Third — and this is the part that elevates hs-CRP from "just a marker" to a clue about mechanism — the CANTOS trial tested whether targeting inflammation directly changes outcomes. It gave canakinumab, an antibody that blocks the inflammatory signal interleukin-1β, to more than 10,000 people who had already had a heart attack and still had elevated hs-CRP. The drug lowered hs-CRP substantially without changing cholesterol at all, and still reduced recurrent cardiovascular events (Ridker et al., 2017, New England Journal of Medicine). That is important: it is some of the best evidence that inflammation is not merely a passenger riding alongside heart disease but part of the causal machinery.
Two cautions keep this honest. The CANTOS drug also had side-effects, including a small increase in fatal infections, so this is a proof of mechanism, not a recommendation for anti-inflammatory drugs in healthy people. And hs-CRP itself is best understood as a marker of the inflammatory process rather than necessarily the molecule doing the damage — lowering CRP is useful chiefly because it reflects lowering the underlying inflammation.
How to read your own number
For everyday interpretation, the long-standing clinical convention comes from a joint scientific statement by the American Heart Association and the U.S. Centers for Disease Control and Prevention, which grouped hs-CRP into three cardiovascular-risk bands (Pearson et al., 2003, Circulation):
- Below 1 mg/L — lower relative risk.
- 1 to 3 mg/L — average relative risk.
- Above 3 mg/L — higher relative risk.
A few practical points make these bands usable. Because CRP rises sharply with any acute illness, a single high reading is often a false alarm — a cold, a recent injury, a vaccination or even a hard training session can push it up transiently. The same AHA/CDC guidance recommends measuring when you are well, and treating a high value as worth repeating a couple of weeks later rather than acting on one spike. Values above roughly 10 mg/L usually point to an acute event rather than chronic inflammatory tone, and are not interpreted as a cardiovascular-risk reading at all.
The signal that matters for ageing is the trend in your baseline when you are healthy — a stable low number over time, rather than any single measurement. That is exactly the kind of pattern a longevity platform is built to track, where one result becomes a line rather than a dot.
What the research associates with a lower hs-CRP
Because hs-CRP reflects a modifiable process, lifestyle is genuinely relevant here — with the usual caveat that most of this evidence is observational or short-term, and lowering a marker is not the same as guaranteeing a longer life.
The clearest interventional signal is exercise. A systematic review and meta-analysis of 83 trials found that exercise training produced a small but statistically significant reduction in CRP, and that the effect was strongest in people who also lost body fat — though reductions occurred even without weight change (Fedewa et al., 2017, British Journal of Sports Medicine). That fits the wider picture in which body fat, particularly visceral fat, is itself a source of inflammatory signalling.
Beyond movement, a broad review of inflammaging and nutrition concluded that diet quality, body weight, the gut microbiome and overall metabolic health all feed into the chronic low-grade inflammation that hs-CRP reflects, and that these are plausible, modifiable levers (Calder et al., 2017, Ageing Research Reviews). The practical themes that recur across this literature are familiar and unglamorous: regular physical activity, maintaining a healthy amount of body fat, a diet rich in whole and plant foods, not smoking, adequate sleep and treating chronic infections or inflammatory conditions. None of these is a quick fix, and none should replace medical care for a diagnosed condition — but each is associated with a quieter inflammatory baseline.
The bottom line
hs-CRP is a cheap, simple blood test that happens to sit on top of one of the deepest currents in ageing biology. On its own, a single value is noisy and non-specific. Tracked over time, in a healthy state, it becomes a useful read-out of the low-grade inflammation — inflammaging — that runs through so many age-related diseases, and one of the few inflammatory signals you can realistically watch and influence. Treat it as a long-run trend rather than a verdict, interpret any high value in context, and use it as one input among several in the bigger picture of how you are ageing.
Sources
- Franceschi C, Bonafè M, Valensin S, et al. Inflamm-aging. An evolutionary perspective on immunosenescence. Annals of the New York Academy of Sciences. 2000;908:244–254. PMID 10911963.
- Franceschi C, Garagnani P, Parini P, Giuliani C, Santoro A. Inflammaging: a new immune-metabolic viewpoint for age-related diseases. Nature Reviews Endocrinology. 2018;14(10):576–590. PMID 30046148.
- Emerging Risk Factors Collaboration. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. The Lancet. 2010;375(9709):132–140. PMID 20031199.
- Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein (JUPITER). New England Journal of Medicine. 2008;359(21):2195–2207. PMID 18997196.
- Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease (CANTOS). New England Journal of Medicine. 2017;377(12):1119–1131. PMID 28845751.
- Fedewa MV, Hathaway ED, Ward-Ritacco CL. Effect of exercise training on C reactive protein: a systematic review and meta-analysis of randomised and non-randomised controlled trials. British Journal of Sports Medicine. 2017;51(8):670–676. PMID 27445361.
- Calder PC, Bosco N, Bourdet-Sicard R, et al. Health relevance of the modification of low grade inflammation in ageing (inflammageing) and the role of nutrition. Ageing Research Reviews. 2017;40:95–119. PMID 28899766.
- Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice. A statement for healthcare professionals from the CDC and the AHA. Circulation. 2003;107(3):499–511. PMID 12551878.
